VivoSeq
Oncology

Multiple Myeloma

884

Pipeline Programs↗

509

Active Trials↗

213

Companies Involved↗

Multiple Myeloma is a highly competitive landscape with 884 programs across 213 companies. The most active players are Chong Kun Dang Pharmaceutical, Celyad Oncology SA, CASI Pharmaceuticals, Inc.. 42 therapies are approved with 114 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

89/100

Mech. Concentration

4/100

Completion Rate

71/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

3 programs

Phase 1C

Celyad Oncology SA

3 programs

Phase 1C

CASI Pharmaceuticals, Inc.

2 programs

Phase 1I

iCell Gene Therapeutics

2 programs

Phase 1N

Nektar Therapeutics

2 programs

Phase 1Sun Pharma Advanced Research Company Limited logo

Sun Pharma Advanced Research Company Limited

2 programs

Phase 1

Pipeline

Programs by Phase

Preclinical48

Ciltacabtagene Autoleucel

St. Olavs Hospital

Idecabtagene Vicleucel

Bristol-Myers Squibb

Denosumab

Amgen

Ixazomib Citrate

Takeda

Interferon Alfa-2b

Merck & Co.

Phase 1292

Hydroxychloroquine

Alnylam Pharmaceuticals

Veliparib

AbbVie

Isatuximab

Azienda U.S.L. 1 di Massa e Carrara

Natalizumab

Biogen

Metformin Hydrochloride

Boehringer Ingelheim

Phase 2388

Tisagenlecleucel

Novartis

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Fludarabine Phosphate

Sanofi

Curcumin

Merck & Co.

Cemiplimab

Regeneron

Phase 3114

Peginterferon Alfa-2b

Merck & Co.

Elotuzumab

Bristol-Myers Squibb

Palifermin

Swedish Orphan Biovitrum

Fludarabine

Sanofi

Panobinostat

SecuraBio

Approved42

Carfilzomib

Virionyx Corporation Limited

Belumosudil

Kadmon, a Sanofi Company

Amifostine

Legacy Health System

Dexamethasone

Aspen Global Incorporated

Palonosetron

Avyxa

Analysis

Modality Breakdown

77%

Small molecule

768 of 1,000 classified programs — the dominant modality here.

23%ALL OTHERSCell therapy10611%Monoclonal antibody636%Protein / enzyme222%Vaccine202%Peptide8<1%RNA therapy6<1%Other7<1%

Small molecule leads; the ring shows all 1,000 classified programs, each share of the total. Modality classified for 99% of 1,136 pipeline programs.

Analysis

Trial Status

1,914

clinical trials

Completed856 · 45%
Terminated274 · 14%
Recruiting246 · 13%
Active, not recruiting188 · 10%
Unknown status170 · 9%
Withdrawn79 · 4%
Other101 · 5%

Clinical Trials

Trial Activity

1914 trials

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Recruiting·KK36 Therapeutics, Inc.·Phase 1·NCT05651932·125 enrolled
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06691685·24 enrolled
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Recruiting·—·Phase 1·NCT06799026·25 enrolled
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT05344833·50 enrolled
VitD3 Supplementation in Patients With Multiple Myeloma
Recruiting·—·Phase 1·NCT05846880·100 enrolled
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Recruiting·EEmory University·Phase 2·NCT04776395·68 enrolled
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting·Sanofi logoSanofi·Phase 2·NCT06356571·64 enrolled
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06158269·40 enrolled
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05055063·30 enrolled
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Recruiting·SShanghai Changzheng Hospital·Phase 1·NCT06407947·10 enrolled
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Recruiting·UUniversity of Rochester·Phase 2·NCT05597345·15 enrolled
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06207799·40 enrolled
Elranatamab in Relapsed/Refractory Multiple Myeloma
Recruiting·UUniversity of California, San Diego·Phase 2·NCT06711705·33 enrolled
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Recruiting·—·Phase 1·NCT06791681·24 enrolled
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Recruiting·OOntario Clinical Oncology Group (OCOG)·Phase 2·NCT06421675·40 enrolled
Page 1 of 128

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)